Investing
GSK sues Pfizer in US for patent infringement over RSV vaccine
© Reuters. FILE PHOTO: A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
2/3
By Blake Brittain
(Reuters) – British biopharmaceutical giant GSK sued Pfizer (NYSE:) in Delaware federal court on Wednesday, accusing Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK’s patent rights in its rival RSV shot Arexvy.
GSK said Pfizer’s vaccine infringes four of its patents related to the antigen its shots use to fight the respiratory disease. Both vaccines were approved for use in adults over 60 by the U.S. Food and Drug Administration in May.
Read the full article here
-
Investing4 days ago
This All-Access Pass to Learning Is Now $20 for Black Friday
-
Passive Income4 days ago
How to Create a Routine That Balances Rest and Business Success
-
Side Hustles5 days ago
Apple Prepares a New AI-Powered Siri to Compete With ChatGPT
-
Side Hustles2 days ago
A Macy’s Employee Made Accounting Errors Worth $132 Million
-
Passive Income5 days ago
Customers Want More Than Just a Product — Here’s How to Keep Up
-
Side Hustles6 days ago
MIT Gives Free Tuition For Families Earning $200,000 or Less
-
Side Hustles4 days ago
Gift the Power of Language Learning with This Limited-Time Price on Babbel
-
Investing1 day ago
Factbox-How Trump can overhaul US financial regulators when he takes office By Reuters